FivepHusion has collaborated with Treehill Partners and Syneos Health to strategically progress development and commercialisation of its chemotherapeutic formulation Deflexifol in markets across the globe.
Under the partnership, Treehill will support FivepHusion with operational, strategic and transactional expertise along with integrated business development.
Syneos will support the commercialisation and clinical development capabilities of FivepHusion.
FivepHusion CEO and managing director Dr Christian Toouli said: “By collaborating with Treehill Partners and Syneos Health, we believe we are positioned to successfully bring our development work on Deflexifol to global markets, including in the US, Europe and Asia.
“Through the combined strength and competency of three industry leaders, we intend to maximise our progress on the development of Deflexifol and quickly bring innovative oncology medicines to patients in need.”
Deflexifol is a new and optimised physiological pH formulation developed for the co-administration of the chemotherapeutic agent 5-fluorouracil (5-FU) and its biomodulator leucovorin (LV).
These drugs are used for the treatment of various solid tumours including gastric, pancreatic, colorectal and breast cancers.
Treehill partner and co-founder Ali Pashazadeh said: “By merging the scientific prowess of our clients with the clinical and commercial expertise of Syneos Health and Treehill’s healthcare advisory and execution capabilities, we are providing a unique ecosystem designed to help companies to flourish despite the current challenging market environment.”
Deflexifol is also being developed to treat paediatric ependymoma, a rare and deadly brain cancer affecting very young children.
Source link
#FivepHusion #collaborates #Treehill #Syneos #Deflexifol
